Accelerated Share Repurchase News Today

• Consolidated revenues were $704 million, up 8.0%, and up 6.9% on an organic constant currency basis for the first quarter of 2024. • Income from continuing operations was $219 million,...

Financial Highlights and Strategic Initiatives Drive Growth

Vishay Intertechnology: "Given Vishays overcapitalized balance sheet, the Board should take advantage of Vishays irrationally low valuation by approving and implementing a $600 million accelerated share repurchase," said the letter, signed by Mountaineer partner Greg Williams said.

Repurchase reflects the strength of United Therapeutics’ balance sheet and confidence in its near-term prospects ...

Despite Headwinds, Company Maintains Strong Gross Profit Margins and Operational Efficiencies

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2023 Earnings Call Transcript February 20, 2024 Halozyme Therapeutics, Inc. reports earnings inline with expectations. Reported EPS is $0.82 EPS, expectations were $0.82. Halozyme Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello […]

Provides 2024 Financial Outlook and New Long-Term Financial Targets ...

Reiterating 2024 Financial Guidance: Total Revenue of $915-985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535-585 Million, Representing...

Launches $450 Million Accelerated Share Repurchase ... -Today at 08:33 am- MarketScreener

STOUGHTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (NASDAQ:COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious